Clinical trials: Heart Failure, Preserved Ejection Fraction
Hypertension Pulmonary Secondary, Heart Failure, Right Sided
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects
- Conditions
- Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
- Trial name
- HELP (NCT03541603)
- Testing
- Levosimendan
- Where
- 16 sites in United States
- Volunteers
- 44 people
- Sponsor
- Tenax Therapeutics, Inc.
Heart Failure
BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction
The purpose of this registry (NCT02876042) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO system in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant…
- Trial name
- HFpEF (NCT02876042)
- Testing
- BAROSTIM NEO™ System
- Where
- 13 sites in Germany
- Volunteers
- 11 people
- Sponsor
- CVRx, Inc.
Systolic Heart Failure, Diastolic Heart Failure
Psychosocial Patterns and Prognosis in Patients With Heart Failure
This prospective observational study is designed to confirm the prognostic and economic impact of depression in ambulatory patients with systolic or diastolic heart failure, to explore the impact of other psychosocial patterns…
- Trial name
- PANIC (NCT00709241)
- Where
- France
- Volunteers
- 325 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
FIRE-HFpEF is a multi-center, prospective, randomized, single-blinded, clinical feasibility study. This study will enroll up to 105 subjects with heart failure with preserved ejection fraction in the United States.
- Trial name
- FIRE-HFpEF (NCT05839730)
- Testing
- Pacemaker PLR + TRT ON, Pacemaker non-pacing mode or an exertional rate-adaptive pacing mode with no planned pacing at rest.
- Where
- 8 sites in United States
- Volunteers
- 105 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Exercise Capacity Improvement by Conduction System Pacing in heArt Failure patieNts Without Compelling CRT inDication
This randomized controlled trial aims to investigate the impact of conduction system pacing in comparison to right ventricular apical pacing on exercise capacity, as measured by peak oxygen uptake (VO2peak), in heart failure…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Heart Conduction Disorder
- Trial name
- ESCPAND (NCT06278844)
- Testing
- Conduction system pacing, Right ventricular apical pacing
- Where
- Belgium
- Volunteers
- 75 people
- Sponsor
- University Hospital, Antwerp
Heart Failure With Preserved Ejection Fraction
Single-Ascending Dose Study of JK07 in Subjects With HFpEF
A phase 1, randomized, double-blind, placebo-controlled single-ascending dose study to assess JK07 in adult subjects with heart failure with preserved ejection fraction.
- Trial name
- NCT05322616
- Testing
- JK07
- Where
- 7 sites in United States
- Sponsor
- Salubris Biotherapeutics Inc
Diastolic Dysfunction
Effect of Dietary Sodium Restriction in the Management of Patients With Heart Failure and Diastolic Dysfunction
Although half of the patients with HF has normal ejection fraction or slightly altered (HF-PEF) and the prognosis differs little from those with reduced ejection fraction, the pathophysiology of HF-PEF is still poorly understood.
- Trial name
- NCT01896908
- Testing
- Sodium restriction
- Where
- Brazil
- Volunteers
- 74 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Pulmonary Hypertension
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
- Trial name
- LEVEL (NCT05983250)
- Testing
- TNX-103
- Where
- 42 sites in United States, Canada
- Volunteers
- 230 people
- Sponsor
- Tenax Therapeutics, Inc.
Heart Failure With Preserved Ejection Fraction, Heart Failure, Congestive
Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure
BACKGROUND: Exercise intolerance is the primary symptom in older patients with heart failure and preserved ejection fraction (HFPEF), however little is known regarding its mechanisms and therapy.
- Trial name
- PIE-I (NCT01411735)
- Testing
- Enalapril
- Volunteers
- 71 people
- Sponsor
- Wake Forest University
Heart Failure With Normal Ejection Fraction
Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction
BACKGROUND There is no effective medical treatment for heart failure with preserved ejection fraction (HFpEF). Increases in pulmonary capillary wedge pressure (PCWP) develop in patients with HFpEF.
- Trial name
- ILO-HOPE (NCT03620526)
- Testing
- Iloprost
- Where
- Taiwan
- Volunteers
- 34 people
- Sponsor
- National Taiwan University Hospital
Heart Failure, Diastolic, Diabetes Mellitus, Type 2
Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus
Patients enrolled into the study will be randomly allocated either to Empagliflozin group or control group. In the Empagliflozin group patients will be receiving standard care + Empagliflozin 10 mg o.d., in the control group…
- Trial name
- NCT03753087
- Testing
- Empagliflozin, Standard care
- Where
- Russia
- Volunteers
- 70 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Transthyretin Amyloid Cardiomyopathy, Heart Failure With Preserved Ejection Fraction
Global Prevalence of ATTR-CM in Participants With HFpEF
This study is a global, multi-center study designed to estimate the global prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) within a clinically at risk population [participants with heart failure with preserved…
- Trial name
- NCT04424914
- Testing
- Scintigraphy
- Where
- 51 sites in United States, Canada and 6 more
- Volunteers
- 347 people
- Sponsor
- Pfizer
Heart Failure, Diastolic, Pulmonary Hypertension
Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PH
Aim of the study is to investigate whether Sildenafil treatment results in a reduction of pulmonary artery pressure without decrease of cardiac output (CO) and in improvement of exercise capacity in patients with heart failure…
- Trial name
- NCT01726049
- Testing
- Sildenafil
- Where
- Netherlands
- Volunteers
- 52 people
- Sponsor
- University Medical Center Groningen
Diastolic Heart Failure, Left Ventricular Diastolic Dysfunction
2 New Measurements Used to Describe the Filling Phase of the Left Ventricle (LV).
As we live longer our population experiencing heart failure (HF) continues to grow consuming an increasing percent of healthcare dollars.
- Conditions
- Diastolic Heart Failure, Left Ventricular Diastolic Dysfunction, Left Ventricular Diastolic Collapse
- Trial name
- INDEX (NCT04154878)
- Where
- United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- AdventHealth
Heart Failure With Preserved Ejection Fraction
Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction
To assess the effect of ARNI on myocardial deoxygenation at stress and myocardial fibrosis, and correlate this to changes in myocardial systolic and diastolic function in HFpEF patients.
- Trial name
- PRISTINE-HF (NCT04128891)
- Testing
- Sacubitril-Valsartan
- Sponsor
- Flinders University
Heart Failure With Preserved Ejection Fraction, Atrial Fibrillation
Exercise Capacity Before and After AF Ablation in Patients With HFpEF
In a prospective, observational pilot study of patients scheduled for an atrial fibrillation (AF) ablation at the University of Vermont Medical Center the investigators will compare exercise capacity before and four months after…
- Trial name
- NCT05376748
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Vermont
Cardiovascular Diseases, Heart Failure
The Safety and Efficacy of Pulsed Field Ablation for Patients With Persistent Atrial Fibrillation Comorbid With HFpEF.
The goal of this clinical trial is to evaluate the the mid- and long-term clinical efficacy and safety of pulsed field catheter ablation for patients with persistent atrial fibrillation and HFpEF.
- Conditions
- Cardiovascular Diseases, Heart Failure, Atrial Fibrillation (AF), HFpEF - Heart Failure With Preserved Ejection Fraction
- Trial name
- NCT07077811
- Testing
- pulsed field ablation, antiarrhythmic drug
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Affiliated Hospital of Nantong University
Heart Failure
Karolinska-Rennes (KaRen) Prospective Study of Exercise Stress Echocardiography in Heart Failure With Preserved Ejection Fraction
Background: Heart failure with preserved ejection fraction (HFPEF) is common but not well understood. Electrical dyssynchrony in systolic heart failure is harmful.
- Trial name
- KaRen (NCT00774709)
- Where
- France
- Volunteers
- 90 people
- Sponsor
- French Cardiology Society
Functional Tricuspid Regurgitation
Echocardiographic Assessment and CLInical imPlication of Functional tricuSpid rEgurgitation in Heart Failure With Reduced or Preserved Ejection Fraction
Purpose Functional tricuspid regurgitation (FTR) has been shown to be associated with increased morbidity and mortality in several clinical conditions, including heart failure (HF) with reduced left ventricular ejection fraction…
- Trial name
- ECLIPSE-HF (NCT05209919)
- Testing
- Transthoracic Echocardiography
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Patients With Heart Failure and Preserved Ejection Fraction - HFpEF, Patients With Heart Failure With Reduced Ejection Fraction - HFrEF
Developing Imaging And plasMa biOmarkers iN Describing Heart Failure With Preserved Ejection Fraction (DIAMONDHFpEF)
The investigators wish to test a hypothesis that patients with HFpEF have different characteristics on echo, cardiac MRI and plasma protein \& chemical profiles compared to HFrEF and healthy volunteers.
- Conditions
- Patients With Heart Failure and Preserved Ejection Fraction - HFpEF, Patients With Heart Failure With Reduced Ejection Fraction - HFrEF, Healthy Controls Group - Age and Sex-matched
- Trial name
- DIAMONDHFpEF (NCT03050593)
- Testing
- MRI scan, Echo scan
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- University of Leicester